1.Free-sugar suspension granule of compound Saliva Miltiorrhiza
Chinese Traditional Patent Medicine 1992;0(12):-
AIM: To select the proper excipients for granule of compound Saliva Miltiorrhiza and the preparative process. METHODS: Building up properties, solubility and resistance to humid were used as the judgement criteria, the kinds and ratio of the excipients and preparative process sieved out. RESULTS: Properere excipent combination consisted of one portion of the extract of compound Salvia Miltiorrhiza, 1.6 times dextin, 2.6% CMC Na, 1% PVP, 2.6% CMS Na. CONCLUSION: The process and its excipent combination is better than the other process of formulation.
2.Applications of nanometer zinc oxide in biomedicine
International Journal of Biomedical Engineering 2015;38(5):306-309,318
Nanometer zinc oxide (Nano-ZnO) has been widely applied in many fields such as rubber,ceramics,textile,cosmetics,etc.due to its excellent physical,chemical and biological properties.In recent years,its applications in biomedicine have been paid more and more attention.This paper introduces the unique optical,chemical,mechanical,semi-conducting and biological properties of Nano-ZnO.Meanwhile,the applications of Nano-ZnO in bio-sensing and detection,biological nutrition,medical treatment,biological imaging,drug delivery,tumor cells targeted killing and translational medicine are also reviewed,and the brief outlook on the applications is presented.
3.The Test of Xuejiejiawei Granule Acute Toxicity The Largest Dose (MTD) of the Determination
Journal of Zhejiang Chinese Medical University 2006;0(05):-
[Objective]Modify Xuejiejiawei Granule judgment toxic particles to guide its clinical drug safety.[Method]Make different dosages,give the mouse to fill stomach,from the observing mouse's physiological condition to judging the medicine toxic.[Result]36 mice after given the medicine observation period do not have an example to die,after the dissection the internal organs have non-pathological changes.[Conclusion] Looking at Xuejiejiawei Granule from the medicine toxic effect,the Xuejie adding the taste pellet is a safe medicine.
4. Comparison of the influnce of gefitinib treatment on quality of life between non-small cell lung cancer patients with high and low ECOG-PS score
Tumor 2013;33(4):339-344
Objective: To explore the quality of life and drug toxicity in NSCLC (non-small cell lung cancer) patients who have a ECOC (Eastern Cooperative Oncology Group)-PS (performance status) score ≥3 and a response to gefitinib more than 6 months, and to explore the possibily of gefitinib applying in NSCLC patients with a ECOG-PS score ≥3. Methods: NSCLC patients histologically and (or) cytologically confirmed were divided into trial group (ECOG-PS score ≥3) and control group (ECOG-PS score ≤2). The patients in the two groups were treated with a dose of 250 mg/d gefitinib. The efficacy, change of quality of life and the toxicity were evaluated. Results: Eighty-eight NSCLC patients were enrolled in this study (trial group: n = 27; control group: n = 61). The median follow-up time was 20.0 months. All patients in the two groups could be évaluable. In the trial group, 4 (14.81%) patients obtained CR (complete response), 20 (74.07%) patients obtained PR (partial response), 3 (11.11%) patients obtained SD (stable disease); the response rate was 88.89% (24/27). In the control group, 10 (16.39%) patients obtained CR (complete response), 43 (70.49%) patients obtained PR (partial response), 8 (13.11%) patients obtained SD (stable disease); the response rate was 86.89% (53/61). There was no difference in response rate between the two groups (P = 0.794). The median time to symptom improvement of the trial group and the control group were 10.0 and 14.0 d, respectively (P = 0.073), the median PFS (progression-free survival) were 8.0 and 7.0 momths, respectively (P = 0.421). The 1-, 2- and 3-year survival rates were 59.269% (16/27), 25.93% (7/27) and 3.70% (1/27) in the trial group and 57.38% (35/61), 21.31% (13/61) and 6.56% (4/61), respectively. There was no difference in survival rate between the two groups (P = 0.180). The ECOG-PS score after gefitinib therapy (vs before gefitinib therapy) was significantly decreased in the two groups (Trial group Z = -4.062, P = 0.000; Control group Z = -4.031, P = 0.000), and the percent decrease of ECOG-PS score after gefitinib therapy in the trial group was significantly higher as compared with that in the control group. The toxicities of gefitinib therapy were tolerated. Conclusion: Gefitinib can be safely applied in NSCLC patients with ECOG-PS score ≥3. There is no difference in survival time between NSCLC patients with ECOG-PS score ≥3 and ≤2, but the quality of life in NSCLC patients with ECOG-PS score 2= 3 is significantly impoved as compard with NSCLC patients with ECOG-PS score ≤2 after gefitinib therapy. Copyright © 2013 by TUMOR.
6.The efficacy of folic acid combined with mecobalamine for the treatment of mild cognitive impairment in patients with cerebral small vessel disease and hyperhomocysteinemia
Zhaohui FU ; Juan WU ; Dengrong CHEN
Chongqing Medicine 2014;(9):1055-1057
Objective To observe the efficacy of folic acid combined with mecobalamine for the treatment of vascular mild cogni-tive impairment (VMCI) in patients with cerebral small vessel disease (SVD) and hyperhomocysteinemia(Hcy) .Methods A total of 84 VMCI patients with cerebral small vessel disease and Hcy were randomly divided into combination group and control group . Two groups received conventional therapy for 6 months .Besides ,the combination group received folic acid combined with mecobal-amin .The level of plasma Hcy and ADAS-cog score were observed before and after 3 months and 6 months treatment .Results Af-ter treatment ,plasma Hcy significantly lower in the combination group (P<0 .01) ,whereas it did not show any improvement in the control group .ADAS-cog scores in combination group decreased compared with that of before treatment ,but there was no statisti-cally significant difference after 3 months treatment(P>0 .05) .However ,after 6 months treatment ,the ADAS-cog scores decreased obviously than that in the before treatment group (P<0 .05) .ADAS-cog scores in control group increased compared with before treatment ,but there was no statistically significant difference in after treatment (P>0 .05) .After 3 months treatment ,there was no significant difference on ADAS-cog score between combination group and control group (P>0 .05) ,however ,there had significant difference between the two groups after 6 months treatment(P<0 .05) .Conclusion The level of plasma Hcy could be reduced by adding folic acid and mecobalamin .Treatment of hyperhomocysteinemia may delay the progression of vascular cognitive impairment w hich caused by cerebral small vessel disease .
7.The Clinical Value of Predicting Premature Birth by to Monitor Cervical withUltrasonography and to test the fetal Fibronectin
Shuo DONG ; Juan FU ; Fengping DENG
Journal of Practical Radiology 2001;0(05):-
Objective To evaluate the relationship between the cervical length,the test of fetal fibronectin and premature birth in pregnant woman.Methods Fetal fibronectin in sample of cervical secretion was tested using the reagent box of FFN manufactured by the ADEIA company of the United States and enzyme-labeled immunosorbent assay(ELISA) methods in 110 pregnant women.They were divided into two groups:first group,there were 60 cases who had symptom of aura prematurity and cervical lengths ≤30 mm monitored by trans-perineum ultrasound.second group was 50 normal pregnant women.Results The postive rate of fetal fibronectin was higher significantly in first group than that in second group.Conclusion The measurement of cervical lengths by the trans-perineum ultrasound and the test of Fetal fibronectin in pregnant women who has symptom of aura prematurity are of certain clinical value in predicting preterm birth.
8.Effect of myopic adolescents wearing orthokeratology lens on the corneal surface curvature radius and anterior chamber depth
Qian, YU ; Juan, LIU ; Min, FU
International Eye Science 2017;17(6):1095-1098
AIM: To analyze the effect of myopic adolescents wearing orthokeratology lens on the corneal surface curvature radius and anterior chamber depth.METHODS: Totally 120 cases of adolescent myopia were selected, among them 58 cases with 116 eyes were divided into 11-14 years old group and 62 cases with 124 eyes were 15-18 years old group according to the age.They were treated with long-term orthokeratology lens treatment, and two groups of patients were observed before wearing lens(T0), wearing for 6mo (T1), 12mo (T2) for uncorrected visual acuity, the average refractive degree improvement, the central corneal thickness, corneal curvature changes and the incidence of complications.RESULTS: The uncorrected visual acuity of the two groups at 12mo after wearing were better than that at 6mo which was better than that before wearing;the diopter had the same trend.The uncorrected visual acuity and the diopter of the 11-14 years old group at 6 and 12mo was better than those of 15-18 years old group with significant difference (P<0.05).The central corneal thickness of the two groups at 12mo after wearing were less than that at 6mo which was less than that before wearing.There was no significant difference of the central corneal thickness between the two groups at 6 and 12mo after wearing (P>0.05).The corneal anterior surface curvature of the two groups at 12mo after wearing were more than that at 6mo which was more than that before wearing.The axial length of the 11-14 years old group was longer than that of the 15-18 years old group with significant difference (P<0.05).There was no significant difference on the corneal posterior surface curvature of the two groups before and after wearing (P>0.05).There was no significant difference on the anterior chamber depth between the two groups at different time or between before and after wearing (P>0.05).CONCLUSION: Long-term wearing orthokeratology lenses have a significant effect for control ling juvenile myopia, and can improve the corneal anterior surface curvature, especially in the lower age group, and has no significant effect on the anterior chamber depth.
9.Clinical study on the treatment of lacrimal duct obstruction with lomefloxacin hydrochloride eye ophthalmic gel
Xiang-Fu, CHENG ; Yue-Juan, ZHAO
International Eye Science 2017;17(9):1793-1795
AIM:To study the clinical effect of silica gel drainage tube combined with lomefloxacin hydrochloride eye ophthalmic gel in the treatment of lacrimal duct obstruction.METHODS:Totally 86 cases (138 eyes) of lacrimal duct embolism treated in our hospital from February to December 2015 were divided into 43 cases (68 eyes) as control group and 43 cases (70 eyes) of the observation group according to whether they were treated with lomefloxacin hydrochloride eye ophthalmic gel.Patients in the control group were treated with silica gel drainage, while the observation group was treated with lomefloxacin hydrochloride eye ophthalmic gel on the basis of the control group.The total effective rate, serum hypersensitivity C-reactive protein (h-CRP) level, complications and recurrence rate were observed and compared between the two groups.RESULTS:The total effective rate in the patients with obstructive nasolacrimal duct, common lacrimal duct obstruction, and lacrimal duct obstruction in observation group were 95.2%, 100.0%, 96.7%, higher than those in control group (P<0.05).There was no significant difference between the two groups in preoperative serum h-CRP levels (P>0.05).The serum levels of h-CRP in patients in the observation group at 3d and 7d after operation respectively were 2.40±0.84g/mL, 1.94±0.84g/mL, lower than those of control group at the same time (P<0.05).The complication rate of the observation group was 1.4%, which was lower than that of the control group (P<0.05).Follow up for 6-18mo, the recurrence rate was 11.4% in the observation group, which was significantly lower than the control group (P<0.05).CONCLUSION:The combination of silica gel drainage tube and lomefloxacin hydrochloride eye ophthalmic gel in the treatment of obstruction of lacrimal duct has good clinical efficacy, low inflammatory reaction, low complication rate and low recurrence rate.
10.The role of ultrasound guided percutaneous ethanol injection for secondary hyperparathyroidism
Juan, LI ; Bin, YANG ; Ning-hua, FU
Chinese Journal of Medical Ultrasound (Electronic Edition) 2013;(11):903-906
Objective To observe and evaluate the effect of ultrasound guided percutaneous ethanol injection for hyperparathyroidism secondary to chronic renal failure. Methods Fifty-three patients with secondary hyperparathyroidism in Nanjing General Hospital Military Command from January 2011 to May 2013 were treated by percutaneous ethanol injection. The echogenicity, size and blood supply of parathyroid glands were observed by color Doppler ultrasound before and after treatment. Parathyroid hormone (PTH) and volumes of parathyroid glands were analyzed and compared with non-paired t test. Results Before treatment, the parathyroid gland volume was (5.28±0.84) cm3. The enlarged parathyroid glands had homogeneous hypoechogenicity and abundant blood supply, and the PTH was (1041.6±37.1) ng/L. After treatment, the size of solitary parathyroid gland was (3.93±0.67) cm3 which did not change significantly compared with that before treatment. The echogenicity of parathyroid glands enhanced and blood supply decreased after injection ethanol into solitary parathyroid. PTH [(509.2±27.6) ng/L] decreased obviously (t=3.792, P < 0.05). Conclusion Color Doppler ultrasound guided percutaneous injection of ethanol has an important role in the treating of secondary hyperparathyroidism and the curative effect can be observed timely.